drugset
drugset / Trial / NCT05216497

Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

NCT05216497 ↗

Phase 3 Completed 233 enrolled Valenta Pharm JSC
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.

Timeline

Start
2021-10-06
Primary completion
2022-01-12
Completion
2022-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ingavirin Small molecule 90 mg —

Indications

COVID-19